Utility:
| This publication evaluates the value of anti-CCP3 as an aid for clinicians to determine which patients to closely follow for early intervention and disease prevention. The study had two objectives. In CCP2 high titer patients the progression to inflammatory arthritis (IA) increased from 38.9 to 48.4% when anti-CCP was also high titer. In addition, the rate of progression dropped with anti-CCP2 was negative. After 3 years of follow-up, approximately 40% of anti-CCP3 positive patients progressed to IA as compared to only 6.3% of CCP3 negative patients. The study provided evidence that there is a higher degree of accuracy in predicting disease progression with the combination of anti-CCP2/CCP3 testing as compared to anti-CCP2 alone |